34
Əlavə 2
Yenidoğulanlarda abstinent sindromunun ağırlığının ballarla
qiymətləndirmək
Cədvəl 8. Yenidoğulanlarda abstinent sindromunun ağırlığının
ballarla qiymətləndirilməsi
Əlamət və yaxud sindromlar
Ballar
MSS tərəfindən pozulmalar
Güclü ağlama 2
Davamlı güclü ağlama 3
Qidalanmadan sonra <1 saat yuxu
3
Qidalanmadan sonra <2 saat yuxu
2
Qidalanmadan sonra <3 saat yuxu
1
Artmış Moro refleksi
2
Kəskin artmış Moro refleksi
3
Həyacan zamanı yüngül tremor
1
Həyacan zamanı mülayım və güclü tremor
2
Dinclik vəziyyətində yüngül tremor
3
Dinclik vəziyyətində mülayim və güclü tremor
4
Əzələlərin hipertonusu
2
Ekskoriasiyalar (xüsusi sahələr) 1
Mioklonlar
3
Yayılmış qıcolmalar 5
Metabolik, vazomotor, nəfəs alma pozulmaları
Tərlilik
1
Qızdırma 37,2-38,2°C
1
Qızdırma 38,4°C və yuxarı 2
Tez tez əsnəmə (>3-4 dəfə) 1
Dərinin mərmərvari olması 1
Burnun tutulması 1
Asqırma >3-4 dəfə 1
Burun qanadlarının körüklənməsi(qanadlarının gərilməsi) 2
Nəfəs almanın tezliyi 1 dəqiqədə 60-dan çox
1
Nəfəs almanın tezliyi 1 dəqiqədə 60-dan çox, döş qəfəsinin elastik
hissələrinin daxilə dartılması ilə
2
Həzm yolu pozulması
Hədsiz acgöz sorma
1
Qidalanma zamanı ləng sorma, tez doyma
2
Tez-tez qaytarma
2
Fontanla qaytarma
3
Duru nəcis 2
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
35
Ədəbiyyat:
1.
2004 report on the global AIDS epidemic. Geneva, Joint United
Nations Programme on HIV/AIDS (UNAIDS), 2004
(http://www.unaids.org/bangkok2004/GAR2004_html/GAR2004_0
0_en.htm, accessed 24 July 2006).
2.
Bartlett JA et al. An updated systematic overview of triple
combination therapy in antiretroviral-naive HIV-infected adults.
12th Conference on Retroviruses and Opportunistic Infections,
Boston, 22—25 February 2005
(www.thebody.com/confs/retro2005/pdfs/croi_586.pdf, accessed 19
June 2006).
3.
Broekmans JF et al. European framework for tuberculosis control
and elimination in countries with low incidence. The European
RespiratorJournal, 2002, 19(4):765—775.
4.
Brown HL et al. Methadone maintenance in pregnancy: a
reappraisal. American Journal of Obstetrics and Gynecology, 1998,
179(2):459—463.
5.
Browne R et al. Outcomes of planned vaginal delivery of HIV-
positive women managed in a multi-disciplinary setting. British
HIV Association/British Association for Sexual Health and HIV,
Dublin, 20-23 April 2005.
6.
Clinical guidelines for the use of buprenorphine in the treatment of
opioid addiction. Rockville, MD, United States Center for
Substance Abuse Treatment, 2004.
7.
Chaisilwattana P et al. Short-course therapy with zidovudine plus
lamivudine for prevention of mother-to-child transmission of human
immunodeficiency virus type 1 in Thailand. Clinical and Infectious
Diseases, 2002, 35(11):1405—1413.
8.
Chasnoff IJ et al. Screening for substance use in pregnancy: a
practical approach for the primary care physician. American Journal
of Obstetrics and Genecology, 2001, 184(4):752—758.
9.
Cooper ER et al. After AIDS Clinical Trial 076: the changing
pattern of zidovudine use during pregnancy, and subsequent
reduction in the vertical transmission of human immunodeficiency
virus in a cohort of infected women and their infants. Journal of
Infectious Diseases 1996, 174:1207—1211.
10.
Cooper ER et al. Combination antiretroviral strategies for the
treatment of pregnant HIV-1-infected women and prevention of
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
36
perinatal HIV-1 transmission. Journal of Acquired Immune
Deficiency Syndromes, 2002, 29:484—494.
11.
Co-operation Group to Combat Drug Abuse and Illicit Trafficking
in Drugs (Pompidou Group). Pregnancy and drug misuse update
2000: proceedings: seminar organized by the Co-operation Group
to Combat Drug Abuse and Illicit Trafficking in Drugs (Pompidou
Group), Strasbourg, France, 29—30 May 2000. Strasbourg, Council
of Europe, 2000.
12.
Coutsoudis A et al. Influence of infant-feeding patterns on early
mother-to-child transmission of HIV-1 in Durban, South Africa: a
prospective cohort study. The Lancet, 1999, 354(9177):471—476.
13.
Dabis F et al. A short course of zidovudine + peripartum neviraİNİe
is highly efficacious in preventing mother-to-child transmission of
HIV-1: the ARNS 1201DITRAME Plus study. 10th Conference on
Retroviruses and Opportunistic Infections, Boston, 10—14 February
2003 (Abstract 854).
14.
Dabis F et al. Effectiveness of a short course of zidovudine +
lamivudine and peripartum neviraİNİe to prevent HIV-1 mother-to-
child transmission: the ANRS DITRAME Plus trial, Abidjan, Cote
d’Ivoire. Antiviral Therapy, 2003, 8 (Suppl. 1):S236—S237.
15.
Dabis F et al. 6-month efficacy, tolerance, and acceptability of a
short regimen of oral zidovudine to reduce verticaltransmission of
HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a
double-blind placebo controlled multicentre trial. The Lancet, 1999,
353(9155):786—792.
16.
Declaration of Commitment on HIV/AIDS. New York, United
Nations General Assembly Special Session (UNGASS)on
HIV/AIDS, 25—27 June 2001
(http://data.unaids.org/publications/irc-
pub03/aidsdeclaration_en.pdf, accessed 24 July 2006).
17.
De Cock KM et al. Prevention of mother-to-child HIV transmission
in resource-poor countries: translating research into policy and
practice. JAMA, 2000, 283(9):1175—1182.
18.
Department of Health Scottish Office, Department of Health Welsh
Office, Department of Health and Social Services of Northern
Ireland. Drug misuse and dependence — guidelines on clinical
management. London, Her Majesty’s Stationery Office, 1999
(http://www.atforum.com/SiteRoot/pages/addiction_resources/UK%
20Methadone%20Guidelines.pdf, accessed 19 June 2006).
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
37
19.
Dorenbaum A et al. Two-dose intrapartum/newborn neviraİNİe and
standard antiretroviral therapy to reduce perinatal HIV transmission:
a randomized trial. JAMA, 2002, 288:189—198.
20.
Dunn DT et al. Risk of human immunodeficiency virus type 1
transmission through breastfeeding. The Lancet, 1992, 340:585—
588.
21.
Eshleman et al. Characterization of neviraİNİe resistance mutations
in women with subtype A vs. D HIV-1 6—8 weeks after single-dose
neviraİNİe (HIVNET 012). Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology, 2004, 35(2):126—130.
22.
European Centre for the Epidemiological Monitoring of AIDS
(EuroHIV). HIV/AIDS surveillance in Europe: end-year report
2004. Saint-Maurice, Institut de Veille Sanitaire, 2005 (No. 71;
http://www.euroİİV.org/reports/index_reports_eng.htm, accessed 24
July 2006).
23.
Finnegan et al. Neonatal abstinence syndrome: assessment and
management. Addictive Diseases International Journal, 1975,
2(1):141—158.
24.
Fisher G et al. Treatment of opioid dependent pregnant women with
buprenorphine. Addiction, 2000, 95(2):239—244.
25.
Giuliano M et al. Selection of resistance mutations in pregnant
women receiving zidovudine and lamivudine to prevent HIV
perinatal transmission. AIDS, 2003, 17(10):1570—1572.
26.
Guay LA et al. Intrapartum and neonatal single-dose neviraİNİe
compared with zidovudine for prevention of mother-tochild
transmission of HIV-1 in Kampala, Uganda: HIVNET 012
randomized trial. The Lancet, 1999, 354(9181):795-802.
27.
HIV and infant feeding: a guide for health-care managers and
supervisors. Geneva, WHO, 2003.
28.
Jackson JB et al. Intrapartum and neonatal single-dose neviraİNİe
compared with zidovudine for prevention of motherto-child
transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of
the HIVNET 012 randomized trial. The Lancet, 2003,
362(9387):859—868.
29.
Kandall SR. Improving treatment for drug-exposed infants.
Rockville, MD, United States Center for Substance Abuse
Treatment, 1993 (Treatment Improvement Protocol Series, No. 5;
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.2412
7, accessed 1 June 2006).
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
38
30.
Lallemant M et al. A trial of shortened zidovudine regimens to
prevent mother-to-child transmission of human immunodeficiency
virus type 1. Perinatal HIV Prevention Trial (Thailand)
Investigators. The New England Journal of Medicine, 2000,
343(14):982—991.
31.
La Porte C et al. Pharmacokinetics of two adjusted dose regimens of
loİNİavir/ritonavir in combination with rifampicin in healthy
volunteers. 42nd Interscience Conference on Antimicrobial Agents
and Chemotherapy, San Diego, 27—30 September 2002 (Abstract
A-1823).
32.
Leroy V et al. Twenty-four month efficacy of a maternal short-
course zidovudine regimen to prevent mother-to-child transmission
of HIV-1 in West Africa. AIDS, 2002, 16(4):631—641.
33.
Leroy V et al. International multicentre polled analysis of late
postnatal mother-to-child transmission of HIV-1 infection. The
Lancet, 1998, 352:597—600.
34.
Mayaux MJ et al. Acceptability and impact of zidovudine for
prevention of mother-to-child human immunodeficiency virus type -
1 transmission in France. The Journal of Pediatrics, 1997,
131:857—862.
35.
Mandelbrot L et al. Lamivudine-zidovudine combination for
prevention of maternal-infant transmission of HIV-1. JAMA, 2001,
285(16):2083—2093.
36.
Medication-assisted treatment for opioid addiction in opioid
treatment programs. Rockville, MD, United States Center for
Substance Abuse Treatment, 2005 (Treatment Improvement
Protocol Series, No. 43;
www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.82676,
accessed 1 June 2006).
37.
Miotti PG et al. HIV transmission through breastfeeding: a study in
Malawi. JAMA, 1999, 282(8):744—749.
38.
Moodley D et al. A multicentre randomized controlled trial of
neviraİNİe versus a combination of zidovudine and lamivudine to
reduce intrapartum and early postpartum mother-to-child
transmission of human immunodeficiency virus type 1. Journal of
Infectious Diseases, 2003, 187(5):725—735.
39.
Nair P. Pharmacological management of neonatal opioid abstinence
syndrome. CNS Drugs, 1997, 8(6):448—456.
40.
Patel A et al. To study the safety and antiretroviral efficacy of
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
39
rifampicin and efavirenz in antiretroviral naïve tuberculosis
coinfected HIV-1 patients in India. 10th Conference on Retroviruses
and Opportunistic Infections, Boston, 10—14 February 2003
(Abstract 138).
41.
Pedral-Samapio D et al. Efficacy of efavirenz 600 mg dose in the ARV
therapy regimen for HIV patients receiving rifampicin in the treatment
of tuberculosis. 10th Conference on Retroviruses and Opportunistic
Infections, Boston, 10-14 February 2003 (Abstract 784).
42.
Pregnancy categories (web page). U.S. Food and Drug
Administration, FDA Consumer magazine, Rockville, MD, United
States, May-June 2001
(www.fda.gov/fdac/features/2001/301_preg.html, 06 October 2006).
43.
Pregnancy, childbirth, postpartum and newborn care: a guide for
essential practice. Geneva, World Health Organization, 2003.
44.
Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant
women with addictions. American Journal of Obstetrics and
Gynecology, 2004, 191(6):1885—1897.
45.
Read P et al. Does zidovudine monotherapy in pregnancy
predispose to the emergence of resistance? HIV Medicine, 2006,
7(Suppl. 1).
46.
Ribera A, Azuaje C, Montero F. Saquinavir, ritonavir, didanosine,
and lamivudine in a once daily regimen for HIV infection in patients
with rifampicin-containing anti-tuberculosis treatment. XIV
International AIDS Conference, Barcelona, 7—12 July 2002
(Abstract ThPeB 7280).
47.
Shaffer N et al. Short-course zidovudine for perinatal HIV-1
transmission in Bangkok, Thailand: a randomized controlled trial:
Bangkok Collaborative Perinatal HIV Transmission Study Group.
The Lancet, 1999, 353(9155):773-780.
48.
Scheduled Caesarean delivery and the prevention of vertical
transmission of HIV infection. International Journal of
Gynaecology and Obstetrics, 2001, 73(3):279—281.
49.
Stern JO et al. A comprehensive hepatic safety analysis of
neviraİNİe in different populations of HIV infected patients. Journal
of Acquired Immune Deficiency Syndromes, 2003, 34:S21—S33.
50.
Strategic approaches to the prevention of HIV infection in infants:
report of a WHO meeting, Morges, Switzerland, 20-22 March 2002.
Geneva, WHO, 2003
(www.who.int/İİV/pub/mtct/en/StrategicApproachesE.pdf, accessed
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
40
7 June 2004).
51.
Strategic framework for the prevention of HIV infection in infants in
Europe. Copenhagen, WHO Regional Office for Europe, 2004
(www.euro.who.int/childhealtdev/manuals/manualstop, accessed 06
October 2006).
52.
Taha TE et al. Short post-exposure prophylaxis in newborn babies to
reduce mother-to-child transmission of HIV-1: NVAZ randomized
clinical trial. The Lancet, 2003, 362(9391):1171—1177.
53.
Thorne C, Newell ML. Are girls more at risk of intrauterine-
acquired HIV infection than boys? AIDS, 2004, 18(2):344—347.
54.
Therapeutic and other interventions to reduce the risk of mother-to-
child transmission of HIV-1 in Europe: the European Collaborative
Study. British Journal of Obstetrics and Gynaecology, 2000,
105:704—709.
55.
The European Mode of Delivery Collaboration. Prelabour
caesarean-section versus vaginal delivery in prevention of vertical
HIV-1 transmission: a randomized clinical trial. The Lancet, 1999,
353:1035—1039.
56.
The International Perinatal HIV Group. The mode of delivery and
the risk of vertical transmission of human immunodeficiency virus
type 1 — a meta-analysis of 15 prospective cohort studies. The New
England Journal of Medicine, 1999, 340:977—987.
57.
The Petra study team. Efficacy of three short-course regimens of
zidovudine and lamivudine in preventing early and late transmission
of HIV-1 from mother to child in Tanzania, South Africa, and
Uganda (Petra study): a randomized, doubleblind, placebo-
controlled trial. The Lancet, 2002, 359(9313):1178—1186.
58.
United States Centers for Disease Control. Updated guidelines for
the use of rifabutin or rifamİNİ for the treatment and prevention of
tuberculosis among HIV-infected patients taking protease inhibitors
or nonnucleoside reverse transcriptase inhibitors. Morbidity and
Mortality Weekly Report, 2000, 49(9):185—189.
59.
Vyankandondera J et al. Reducing risk of HIV-1 transmission from
mother to infant through breastfeeding using antiretroviral prophylaxis
in infants (SIMBA). 2nd IAS Conference on HIV Pathogenesis and
Treatment, Paris, 13—16 July 2003 (Abstract LB7).
60.
Wiktor SZ et al. Short-course oral zidovudine for prevention of mother-
to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomized
trial. The Lancet, 1999, 353(9155):781—785.
Klinik protokol Azərbaycan Respublikası Səhiyyə Nazirliyinin
İctimai Səhiyyə və İslahatlar Mərkəzində hazırlanmışdır.
Document Outline 3>2>1>
Dostları ilə paylaş: |